Metabolex Completes Patient Enrollment In Phase 2 Trial Of MBX-8025 For Treatment Of Dyslipidemia

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has completed enrollment in a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides.

More: continued here

Filed under: Cholesterol on June 19th, 2008